It was observed that the percentage of S% phase and G2-M% were reduced compared to the control in both MCF-7 and MDA-MB-231 breast cancerous cell lines treated with the combination therapy of thymoquinone and TRAIL, while the percentage of G0-G1% was increased (G0-G1% phase arrest) in both cells treated with both compounds, which indicate the positive effect of test compounds on these cancer cells in-vitro. Here, TNFSF10 is linked to cancer.